Sanofi-Aventis becomes a 'major biotechnology partner'
19 June 2008 00:00 in Pharmaceutical Company Restructures
Sanofi-Aventis has announced its progress in biotechnology over the past year, reporting that it has become a major partner in the field.
The company told the international convention of the Biotechnology Industry Organisation it has signed nine major agreements in biotechnology in the past 12 months, describing itself as a partner of choice for the development of molecules and vaccines for the future.
It also informed the convention that six new vaccines and three new therapeutic antibodies are now in development as a result of its recent collaborations.
Major research and development agreements signed by Sanofi-Aventis in the past year have included those with Regeneron, Dyax, Acambis and the Institute of Haematology and Blood Diseases Hospital at the Chinese Academy of Medical Sciences, Tianjin, China.
Marc Cluzel, senior vice-president of research and development at Sanofi-Aventis, said: "By expanding our research and development partnering activities, we shall complete our portfolio and offer more innovative solutions to improve patients' lives."
He added that the company is developing a proactive partnership agenda in order to remain at the forefront of research, with a focus on biotherapy and biotechnology.
In November 2007, Sanofi-Aventis announced plans to build a new influenza vaccine facility in Shenzhen, China.
Other news stories from 19/06/2008
Recent news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
